VERISANTE TECHNOLOGY Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VERISANTE TECHNOLOGY

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: DinoNavarre	10/20/2011 10:32:09 AM
	of 254

Zacks checks in............... Aura Approved in Canada! October 20, 2011 \| Comments: 0 Aura Approved in Canada! Brian Marckx, CFA Health Canada Approval This morning (10/19/2011) Verisante Technology ( V.VRS - Analyst Report, VRSEF) announced that they received marketing approval from Health Canada to market Aura. This marks a major milestone for Verisante and is a testament to the company's ability to get Aura commercialized. Verisante will now begin preparations for the roll-out in Canada. CE Mark for approval to sell Aura in Europe and Australia is next in line - which could come by the current year-end. As we've noted in the past, the initial roll-out will be a progressive process and, as a result, we model only limited revenue through the end of 2012. By that time, Verisante's distribution and production should be in full-swing and revenue could begin to ramp much faster. Financial Model We have made no changes to our model as a result of today's announcement as we had been anticipating the news. We also have not adjusted our price target (remains at $2.60/share), although we feel Canadian regulatory approval reduces downside risk in the share price and provides further support that the stock trades cheaper than warranted. While the stock is up over 125% since we initiated coverage of Verisante in February, we think it could still triple from today's price ($0.88) over the course of the next six months. To view our most recent research reports and subscribe to our daily morning email alert, visit http://scr.zacks.com/. Please email scr@zacks.com with VRS.V as the subject to request a free copy of the full research report. Follow Zacks Small Cap Research on Twitter at Twitter.com/ZacksSmallCap

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next